
Healthcare · BSE
Speciality Medicines Limited was incorporated in 2021 and focuses on marketing and distributing speciality pharmaceutical medicines, including expensive oral and injectable drugs used to treat serious and long-term health conditions in both Indian and international markets. The company offers many types of finished pharmaceutical products in different forms such as tablets, capsules, creams, syrups, eye drops, gels, injections, inhalers, nasal sprays, ointments, sachets, and suspensions. It operates through two main models: contract manufacturing of finished medicines for international markets and marketing and distribution of speciality medicines sourced from other manufacturers. The company has expanded globally with products registered or under registration in countries like Jordan, Ethiopia, Uganda, Peru, and Namibia, and its distribution network covers more than 20 states in India and over 35 countries worldwide. As of March 31, 2025, one product was registered overseas and 60 products were under registration in five countries, contributing to revenue, and as of August 31, 2025, the company had 18 permanent employees working in different departments.
Price Band
₹117 – ₹124
Issue Size
₹235.00 L Cr
Lot Size
1000 shares
GMP
Est. Listing
₹124
at current GMP
Subscribed
2.33x
overall
Open
20 Mar 2026
Close
24 Mar 2026
Allotment
25 Mar 2026
Refund
26 Mar 2026
Demat Credit
27 Mar 2026
Listing
30 Mar 2026
Designated Registrar: Skyline Financial Services Private Limited
Allotment Date
25 Mar 2026
Basis finalization
Refunds Initiate
26 Mar 2026
Mandate release
Demat Credit
27 Mar 2026
Shares in demat
Listing Debut
30 Mar 2026
Trading begins
Speciality Medicines Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹23,50,000 Crores. The shares are offered at a price band of ₹117 to ₹124 per equity share on BSE. Currently, market analysts recommend evaluating the company's financial valuation, price-to-earnings (P/E) multiple, and peer comparison prior to submitting bids.
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Following the close of bidding on 2026-03-24, the basis of allotment is scheduled to be finalized on 2026-03-25. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Skyline Financial Services Private Limited) or the BSE allotment checking window.
Allotment records are updated in batches. If the status is not yet available, please wait a few hours until the basis of allotment is fully finalized.
Since funds are blocked under ASBA/UPI, the bank will automatically release the blocked hold on your funds upon receipt of revocation instructions from the sponsor bank.